EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Nadja Meumann, Marti Cabanes-Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora iD, Qinggong Yuan, Karin Nien-Huber, Ahmed Abdelrahman, Xuan-Khang Vu, Liang Zhang, Ann-Christin Franke, Christian Schmithals und 14 weitere

Hepatology · 2023

DOI: 10.1002/hep.32733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology, 2023. Verfasst von Nadja Meumann und 25 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Hematology , Hannover Medical School , Hannover , Germany. Hauptthemen laut MEDLINE: Capsid, Dependovirus. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural serotypes by peptide insertion has so far been less successful. Here, we now report on two capsid variants, MLIV.K and MLIV.A, both derived from a high‐throughput in vivo AAV peptide display selection screen in mice. Approach and Results: The variants transduce primary murine and human hepatocytes at comparable efficiencies, a valuable feature in clinical development, and show significantly improved liver transduction efficacy, thereby allowing a dose reduction, and outperform parental AAV2 and AAV8 in targeting human hepatocytes in humanized mice. The natural heparan sulfate proteoglycan binding ability is markedly reduced, a feature that correlates with improved hepatocyte transduction. A further property that might contribute to the improved transduction efficacy is the lower capsid melting temperature. Peptide insertion also caused a moderate change in sensitivity to human sera containing anti‐AAV2 neutralizing antibodies, revealing the impact of epitopes located at the basis of the AAV capsid protrusions. Conclusions: In conclusion, MLIV.K and MLIV.A are AAV peptide display variants selected in immunocompetent mice with improved hepatocyte tropism and transduction efficiency. Because these features are maintained across species, MLIV variants provide remarkable potential for translation of therapeutic approaches from mice to men.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapsidDependovirusAnimalsMiceHumansSerogroupTransduction, GeneticGenetic VectorsLiverPeptidesGenetic Therapy

Substanzen

Peptides

Autor:innen und Institutionen

  • Institute of Experimental Hematology , Hannover Medical School , Hannover , Germany.
  • Center for Molecular Medicine Cologne , University of Cologne , Cologne , Germany.
  • Translational Vectorology Research Unit , Children's Medical Research Institute , The University of Sydney , Sydney , New South Wales , Australia.
  • Institute for Drug Discovery , University Leipzig Medical School , Leipzig , Germany.
  • Center for Scalable Data Analytics and Artificial Intelligence ScaDS.AI , Dresden/Leipzig , Germany.
  • Cancer Research Center of Lyon , Institut National de la Santé et la Recherche Médicale , Lyon , France.

ORCID-Profile: Julie Lucifora, Margarete Odenthal, Hildegard Büning

Zitieren

APA

Meumann, N., Cabanes-Creus, M., Ertelt, M., Navarro, R. G., Lucifora, J., Yuan, Q., Nien-Huber, K., Abdelrahman, A., Vu, X. K., Zhang, L., Franke, A. C., Schmithals, C., Piiper, A., Vogt, A., Gonzalez-Carmona, M., Frueh, J. T., Ullrich, E., Meuleman, P., Talbot, S. R., …, & Büning, H. (2023). Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy. Hepatology. https://doi.org/10.1002/hep.32733

Vancouver

Meumann N, Cabanes-Creus M, Ertelt M, Navarro RG, Lucifora J, Yuan Q, et al. Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy. Hepatology. 2023. doi:10.1002/hep.32733

BibTeX
@article{Meumann2023,
  author = {Meumann, Nadja and Cabanes-Creus, Marti and Ertelt, Moritz and Navarro, Renina Gale and Lucifora, Julie and Yuan, Qinggong and Nien-Huber, Karin and Abdelrahman, Ahmed and Vu, Xuan-Khang and Zhang, Liang and Franke, Ann-Christin and Schmithals, Christian and Piiper, Albrecht and Vogt, Annabelle and Gonzalez-Carmona, Maria and Frueh, Jochen T and Ullrich, Evelyn and Meuleman, Philip and Talbot, Steven R and Odenthal, Margarete and Ott, Michael and Seifried, Erhard and Schoeder, Clara T and Schwäble, Joachim and Lisowski, Leszek and Büning, Hildegard},
  title = {Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy},
  journal = {Hepatology},
  year = {2023},
  doi = {10.1002/hep.32733}
}
Kostenlos starten →